The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
Bradley J. Monk
Research Funding - Array BioPharma
Rachel N. Grisham
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Susana N. Banerjee
Research Funding - Array BioPharma
Felix Hilpert
No relevant relationships to disclose
Robert L. Coleman
No relevant relationships to disclose
Eric Pujade-Lauraine
No relevant relationships to disclose
Sandro Pignata
No relevant relationships to disclose
Mansoor Raza Mirza
No relevant relationships to disclose
Amit M. Oza
Research Funding - Array BioPharma
Josep M. del Campo
No relevant relationships to disclose
Martin Klaus Oehler
No relevant relationships to disclose
Adam James
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Janna Christy-Bittel
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Emma Barrett
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Adam P. Boyd
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Ignace Vergote
Consultant or Advisory Role - Array BioPharma